Digital tomosynthesis compared to chest radiography for pulmonary nodule screening and determining case management.
Digital tomosynthesis outperformed conventional chest radiography for lung nodule detection and determination of case management, according to a study published in Radiology.
Researchers from the United States and Sweden conducted a multi-institutional, multireader study to compare the performance of digital tomosynthesis, dual-energy (DE) imaging, and conventional chest radiography to screen for and manage pulmonary nodules.
A total of 158 subjects (43 with normal findings) participated in the study. All underwent chest CT and imaging with conventional chest radiography, DE imaging, and tomosynthesis. The chest CTs were read by three experienced thoracic radiologists, who then recommended case management. Another five radiologists marked nodules and indicated case management by using images from conventional chest radiography, conventional chest radiography plus DE imaging, tomosynthesis, and tomosynthesis plus DE imaging. Results were further analyzed according to nodule diameter categories (3 to 4 mm, greater than 4 mm to 6 mm, greater than 6 mm to 8 mm, and greater than 8 mm to 20 mm).
The results showed that tomosynthesis was superior to conventional chest radiography for lung nodule detection and determination of case management. The maximum lesion localization fraction was higher for tomosynthesis than for conventional chest radiography in all nodule size categories (3.55-fold for all nodules). Case-level sensitivity was higher with tomosynthesis than with conventional chest radiography for all nodules (1.49-fold), and case management decisions showed better overall accuracy with tomosynthesis than with conventional chest radiography, as given by the area under the receiver operating characteristic curve (1.23-fold). The researchers did not find any differences in any specificity measures and DE imaging did not significantly affect nodule detection when paired with either conventional chest radiography or tomosynthesis.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.